PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Actinium Pharmaceuticals, Inc. (ATNM)
1.780.01 (-0.56%)
1.75 - 1.81
1.03 - 2.41
122.5K / 297.6K (Avg.)
-1.36 | -1.31
Gauges a company's financial stability and solvency. Value investors pay close attention to leverage and liquidity risk, ensuring the company has enough cushion to withstand downturns without impairing shareholder value.
0.01
D/E of 0.01 while GNPX has all-equity financing. Bruce Berkowitz would demand higher returns to justify our leverage.
5.03
Net debt while GNPX maintains net cash position. John Neff would demand higher returns to justify the additional leverage risk.
-2258.10
Negative coverage while GNPX shows 0.00. Joel Greenblatt would look for operating improvements and turnaround potential.
7.05
Current ratio of 7.05 while GNPX has zero ratio. Bruce Berkowitz would examine if our working capital management provides advantages.
No Data
No Data available this quarter, please select a different quarter.